The NeuroStar TMS therapy device was the first TMS Therapy System cleared by the FDA to treat adult patients with Major Depressive Disorder (MDD) who have not benefited from prior antidepressant medication and uses a highly targeted, pulsed magnetic field to stimulate function in brain regions known to affect mood. The magnetic field used in the TMS device is similar in strength and type to the magnetic field produced by an MRI machine.

  • Clinical trials have demonstrated the safety of Neurostar TMS therapy. Treatment with TMS caused very few side effects and was generally well tolerated by patients.
  • The most common side effect reported during clinical trials was scalp discomfort—generally mild to moderate and occurring less frequently after the first week of treatment.
  • No systemic side effects
  • No adverse effects on concentration or memory
  • No drug interactions
  • TMS Therapy should not be used in patients with implanted metallic devices or non-removable metallic objects in or around the head. This does not include metallic fillings in teeth.
  • TMS Therapy should not be used in patients with implants controlled by physiological signals. This includes pacemakers and implantable cardioverter defibrillators (ICDs).